Phosphatidylserine for Memory: What the Evidence Shows

Phosphatidylserine (PS) has something most nootropics lack: an FDA-sanctioned health claim. That claim is weaker than supplement marketers would like you to think, and there is a complication with the evidence that rarely makes it onto the product label. The supplement you can buy today is not the supplement that was studied in the trials that earned the health claim. That distinction is the entire story of phosphatidylserine.

The diagnostic pause

PS is not a treatment for the medical conditions that cause most brain fog. If your fog comes from hypothyroidism, iron-deficiency anemia, depression, or poor sleep, PS will not address the underlying problem. Those conditions have specific, effective treatments, and no phospholipid supplement is among them. Treatable causes come first. A blood panel and a conversation with a doctor is the correct starting point for persistent brain fog, and it is a faster, cheaper, and more reliable route to improvement than anything on the supplement shelf.

This applies to PS as much as it applies to any other supplement, but it is worth emphasizing because the FDA health claim gives PS an appearance of authority that can lead people to skip the diagnostic step. An FDA-qualified health claim does not mean “this works.” It means the evidence was not strong enough for a standard health claim but was not so weak that the claim would be misleading. That is a lower bar than it sounds.

What phosphatidylserine is

PS is a phospholipid, a type of fat molecule that forms a major component of cell membranes, particularly in the brain. It is concentrated on the inner leaflet of neuronal cell membranes, where it participates in cell signaling, apoptosis (programmed cell death), and the release of neurotransmitters including acetylcholine and dopamine. The body synthesizes PS endogenously, and it is also obtained through diet, primarily from organ meats, fish, and soybeans.

The mechanistic rationale for PS supplementation is based on its structural importance in neuronal membranes and its role in neurotransmitter release. In theory, supplementing PS could support membrane integrity and signaling efficiency. Whether it does so in practice, in people whose endogenous synthesis is normal and whose diet provides adequate PS, is the question the clinical evidence needs to answer.

The bovine vs. soy problem

This is the detail that most PS marketing omits, and it is the most important detail in the entire PS evidence base.

The clinical trials that produced the most convincing positive results used PS derived from bovine cortex, cow brain tissue. These trials were conducted in the late 1980s and early 1990s, before BSE (bovine spongiform encephalopathy, commonly known as mad cow disease) became a public health concern.

Crook et al. (1991) tested 300mg/day of bovine cortex-derived PS in 149 patients with age-associated memory impairment over 12 weeks and found significant improvements in memory-related tasks compared to placebo [1]. This was a well-designed, double-blind RCT with a reasonable sample size, and the result was clear. Memory scores improved, and the improvement was clinically meaningful within the population studied.

Cenacchi et al. (1993) conducted a larger multicenter RCT of 494 elderly patients with cognitive impairment, also using 300mg/day of bovine-derived PS over 6 months [5]. The results were similarly positive: significant improvements in behavior and cognitive function compared to placebo. At nearly 500 participants, this is one of the larger supplement trials in the cognitive aging literature.

These were real results from well-designed trials in relevant populations. The evidence was genuine. Then BSE became a concern, the theoretical risk of prion transmission from bovine brain tissue became unacceptable, and bovine brain-derived PS was removed from the supplement market. The supplements on shelves today are soy-derived.

The switch matters because bovine PS and soy PS are not biochemically identical. They share the same phospholipid head group (phosphatidylserine), but their fatty acid tails are different. Bovine PS contains primarily DHA and other long-chain omega-3 fatty acids, which are themselves associated with brain health. Soy PS contains primarily linoleic acid and palmitic acid [4]. These are chemically distinct molecules that happen to share a name because of the shared head group. Whether they produce the same biological effects in the brain is not established, and the available evidence suggests they may not.

Glade and Smith (2015), in their review of PS and the human brain, note this distinction explicitly and conclude that soy PS may not replicate the effects of bovine PS [4]. The positive trials were conducted with bovine PS. The product on the shelf is soy PS. The evidence from one does not automatically apply to the other.

What the evidence shows for soy PS

Kato-Kataoka et al. (2010) tested soy-derived PS in 78 elderly Japanese subjects with memory complaints, using doses of 100-300mg/day over 6 months [2]. The results showed some improvement in memory scores compared to placebo. This is a positive finding, but it comes from a small trial with acknowledged methodological limitations, including a small sample size and a population that may not be representative of the broader supplement-buying public.

No large, well-designed RCT has demonstrated clear cognitive benefits from soy-derived PS in any population. The evidence base for the product actually available to consumers is thin, and the thinner it is, the more weight the FDA-qualified health claim carries in marketing, which is a problem because that claim was granted based partly on the bovine PS evidence.

In healthy younger adults

No clinical trial has tested PS for cognitive function or brain fog in healthy younger adults, whether bovine-derived or soy-derived. The entire evidence base is in older adults with existing cognitive decline or memory complaints. The person buying PS at the supplement store because they feel foggy is not represented in any trial.

This absence is not unique to PS; it describes many nootropics. But it is particularly notable for PS because the FDA health claim gives the impression that the evidence is stronger and more broadly applicable than it actually is.

The FDA qualified health claim

The FDA granted PS a qualified health claim in 2003. The specific language the agency requires is: “Very limited and preliminary scientific research suggests phosphatidylserine may reduce the risk of dementia in the elderly” and “Very limited and preliminary scientific research suggests phosphatidylserine may reduce the risk of cognitive dysfunction in the elderly” [3].

The qualifiers are not optional. They are the FDA’s assessment of the evidence, and they are the weakest language the agency attaches to any health claim. The system has four levels: “significant scientific agreement” (the strongest), “some scientific evidence,” “limited scientific evidence,” and “very limited and preliminary” (the weakest). PS sits at the bottom.

The FDA was explicit in its review that the evidence was not convincing, but that it was not misleading either, provided the qualifier was included. Supplement marketers often cite the existence of the health claim without the qualifier. The qualifier is the important part. It is the FDA saying, essentially, “We cannot stop you from saying this, but you must also tell consumers that the evidence is not strong.”

Verdict

Weak. The positive clinical evidence is primarily from bovine-derived PS, which is no longer available. The trials using bovine PS were reasonably well-designed and showed genuine benefits in older adults with cognitive decline, but the product is no longer on the market. The soy-derived PS sold today has a different fatty acid profile, and its evidence base is limited to a single small trial with methodological limitations. The FDA health claim exists but is in the weakest possible category, with mandatory language stating the evidence is “very limited and preliminary.” No evidence exists for brain fog in healthy younger adults, with either form of PS.

The gap between what is marketed and what is demonstrated is one of the widest in the nootropic aisle. A product that can legally say “may reduce the risk of dementia” while being required to say “very limited and preliminary scientific research suggests” in the same sentence is not a product whose evidence speaks clearly.

What remains unknown

Whether soy PS at higher doses would produce better results than the Kato-Kataoka trial found is untested. Whether combining soy PS with DHA supplementation, to more closely approximate the fatty acid profile of bovine PS, would recover the effects seen in the bovine trials is an interesting hypothesis that no one has studied. The mechanism by which bovine PS produced positive results, whether through the PS head group itself, the DHA content in the fatty acid tails, or both acting together, has not been clearly established, and this question has practical implications for whether any form of supplemental PS can deliver the benefits the earlier trials showed. Whether PS supplementation helps any specific cause of brain fog, rather than age-related cognitive decline generally, is unknown.

If brain fog is new, persistent, or affecting daily life. See a doctor. Brain fog can be caused by conditions that are straightforward to treat once identified, including thyroid disorders, anemia, sleep apnea, and depression. A blood panel and a conversation with a GP is the first step, before any supplement.